[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RU2487935C2 - Cell lines of madin-derby canine kidney supporting virus growth to high tires and method to use these cells in bioreactor - Google Patents

Cell lines of madin-derby canine kidney supporting virus growth to high tires and method to use these cells in bioreactor Download PDF

Info

Publication number
RU2487935C2
RU2487935C2 RU2009113671/10A RU2009113671A RU2487935C2 RU 2487935 C2 RU2487935 C2 RU 2487935C2 RU 2009113671/10 A RU2009113671/10 A RU 2009113671/10A RU 2009113671 A RU2009113671 A RU 2009113671A RU 2487935 C2 RU2487935 C2 RU 2487935C2
Authority
RU
Russia
Prior art keywords
mediv
mdck
influenza virus
glucose
cell line
Prior art date
Application number
RU2009113671/10A
Other languages
Russian (ru)
Other versions
RU2009113671A (en
Inventor
Джонатан Лю
Ричард ШВАРТЦ
Марк Томпсон
Луиш МАРАНГА
Саймон СУ
Мридул ГОШ
Аджит СУБРАМАНИАН
Original Assignee
Медиммун, Ллк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиммун, Ллк. filed Critical Медиммун, Ллк.
Publication of RU2009113671A publication Critical patent/RU2009113671A/en
Application granted granted Critical
Publication of RU2487935C2 publication Critical patent/RU2487935C2/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C12N2760/16252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

FIELD: biotechnologies.
SUBSTANCE: new strains of Madin-Derby canine kidney cells (MDCK) are described. Strains are used to cultivate viruses, in particular, a flu virus, in cell culture to a higher titre compared to previously achieved titres. MDCK cells may be adapted to cultural medium without serum. Also the method is described to produce flu viruses in cell culture, where MDCK cells are used according to this invention.
EFFECT: higher efficiency of strain application.
28 cl, 20 dwg, 20 tbl, 14 ex

Description

Текст описания приведен в факсимильном виде.

Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
Figure 00000110
Figure 00000111
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115
Figure 00000116
Figure 00000117
Figure 00000118
Figure 00000119
Figure 00000120
Figure 00000121
Figure 00000122
Figure 00000123
Figure 00000124
Figure 00000125
Figure 00000126
Figure 00000127
Figure 00000128
Figure 00000129
Figure 00000130
Figure 00000131
The text of the description is given in facsimile form.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
Figure 00000110
Figure 00000111
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115
Figure 00000116
Figure 00000117
Figure 00000118
Figure 00000119
Figure 00000120
Figure 00000121
Figure 00000122
Figure 00000123
Figure 00000124
Figure 00000125
Figure 00000126
Figure 00000127
Figure 00000128
Figure 00000129
Figure 00000130
Figure 00000131

Claims (28)

1. Линия клеток почки собаки Майдин-Дэрби (MDCK), депонированная в коллекции АТСС под номером РТА-7909 и поддерживающая репликацию адаптированного к холоду вируса гриппа до выраженной десятичным логарифмом величины средней инфицирующей культуру ткани дозы на миллилитр (log10 TCID50/мл), составляющей по меньшей мере примерно 7,8 или выше, или до выраженного десятичным логарифмом количества единиц флуоресцентного фокусирования на миллилитр (log10 FFU/мл), составляющего по меньшей мере примерно 7,8 или выше; причем композиция культуры клеток этой линии включает множество клеток MDCK и среду для культивирования клеток, которая не содержит сыворотки, выбранную из группы, состоящей из сред MediV-105, MediV-105 с добавлением глюкозы, М-32, М-32 с добавлением глюкозы, MediV-107, MediV-107 с добавлением глюкозы.1. Maidin-Derby dog kidney cell line (MDCK), deposited in the ATCC collection under the number PTA-7909 and supporting replication of cold-adapted influenza virus to the decimal logarithm of the average tissue culture dose per milliliter (log 10 TCID 50 / ml) of at least about 7.8 or higher, or up to the number of fluorescence focusing units per milliliter (log 10 FFU / ml) expressed as a decimal logarithm of at least about 7.8 or higher; moreover, the composition of the cell culture of this line includes many MDCK cells and cell culture medium that does not contain serum, selected from the group consisting of MediV-105, MediV-105 with glucose, M-32, M-32 with glucose, MediV-107, MediV-107 with the addition of glucose. 2. Линия клеток MDCK по п.1, причем клетки MDCK являются агрегированными, неопухолеродными и/или незлокачественными.2. The MDCK cell line according to claim 1, wherein the MDCK cells are aggregated, non-tumorous and / or non-cancerous. 3. Линия клеток MDCK по п.1 или 2, причем вирус гриппа аттенуирован.3. The MDCK cell line according to claim 1 or 2, wherein the influenza virus is attenuated. 4. Линия клеток MDCK по пп.1, 2 или 3, причем вирус гриппа чувствителен к температуре.4. The MDCK cell line according to claims 1, 2 or 3, wherein the influenza virus is temperature sensitive. 5. Линия клеток MDCK по любому из пп.1-4, где вирус гриппа включает один или несколько генных сегментов штаммов вируса гриппа A/Ann Arbor/6/60 или B/Ann Arbor/1/66.5. The MDCK cell line according to any one of claims 1 to 4, where the influenza virus includes one or more gene segments of strains of the influenza virus A / Ann Arbor / 6/60 or B / Ann Arbor / 1/66. 6. Линия клеток по п.1, где средой для культивирования клеток является среда MediV-105 или MediV-105 с добавлением глюкозы.6. The cell line of claim 1, wherein the cell culture medium is MediV-105 or MediV-105 supplemented with glucose. 7. Линия клеток почки собаки Майдин-Дэрби (MDCK), депонированная в коллекции АТСС под номером РТА-7910 и поддерживающая репликацию адаптированного к холоду вируса гриппа до выраженной десятичным логарифмом величины средней инфицирующей культуру ткани дозы на миллилитр (log10 TCID50/мл), составляющей по меньшей мере примерно 7,8 или выше, или до выраженного десятичным логарифмом количества единиц флуоресцентного фокусирования на миллилитр (log10 FFU/мл), составляющего по меньшей мере примерно 7,8 или выше; причем композиция культуры клеток этой линии включает множество клеток MDCK и среду для культивирования клеток, которая не содержит сыворотки, выбранную из группы, состоящей из сред MediV-105, MediV-105 с добавлением глюкозы, М-32, М-32 с добавлением глюкозы, MediV-107, MediV-107 с добавлением глюкозы.7. Maidin-Derby dog kidney cell line (MDCK), deposited in the ATCC collection under the number PTA-7910 and supporting replication of cold-adapted influenza virus to the decimal logarithm of the average tissue culture dose per milliliter (log 10 TCID 50 / ml) of at least about 7.8 or higher, or up to the number of fluorescence focusing units per milliliter (log 10 FFU / ml) expressed as a decimal logarithm of at least about 7.8 or higher; moreover, the composition of the cell culture of this line includes many MDCK cells and cell culture medium that does not contain serum, selected from the group consisting of MediV-105, MediV-105 with glucose, M-32, M-32 with glucose, MediV-107, MediV-107 with the addition of glucose. 8. Линия клеток MDCK по п.7, причем клетки MDCK являются агрегированными, неопухолеродными и/или незлокачественными.8. The MDCK cell line according to claim 7, wherein the MDCK cells are aggregated, non-tumorous and / or non-cancerous. 9. Линия клеток MDCK по п.7 или 8, причем вирус гриппа аттенуирован.9. The MDCK cell line according to claim 7 or 8, wherein the influenza virus is attenuated. 10. Линия клеток MDCK по пп.7, 8 или 9, причем вирус гриппа чувствителен к температуре.10. The MDCK cell line according to claims 7, 8 or 9, wherein the influenza virus is temperature sensitive. 11. Линия клеток MDCK по любому из пп.8-10, где вирус гриппа включает один или несколько генных сегментов штаммов вируса гриппа A/Ann Arbor/6/60 или B/Ann Arbor/1/66.11. The MDCK cell line according to any one of claims 8 to 10, wherein the influenza virus comprises one or more gene segments of the influenza virus strains A / Ann Arbor / 6/60 or B / Ann Arbor / 1/66. 12. Линия клеток по п.11, где средой для культивирования клеток является среда MediV-105 или MediV-105 с добавлением глюкозы.12. The cell line of claim 11, wherein the cell culture medium is MediV-105 or MediV-105 supplemented with glucose. 13. Способ репликации вируса гриппа в системе биореактора однократного применения (SUB), включающий:
(а) культивирование клеток почки собаки Майдин-Дэрби MDCK по любому из пп.1-5 и 7-11 в системе биореактора однократного применения (SUB) в присутствии микроносителя при культуральных условиях, которые предусматривают перемешивание, и продуцирование, таким образом, культивируемых клеток,
(б) инфицирование клеток вирусом гриппа с получением инфицированных клеток,
(в) инкубирование инфицированных клеток в условиях, допускающих репликацию вируса гриппа.13. A method for replicating an influenza virus in a single use bioreactor (SUB) system, comprising:
(a) culturing the Maidin-Derby MDCK dog kidney cells according to any one of claims 1-5 and 7-11 in a single-use bioreactor system (SUB) in the presence of a microcarrier under culture conditions that involve mixing and thereby producing cultured cells ,
(b) infection of cells with influenza virus to obtain infected cells,
(c) incubation of infected cells under conditions that allow replication of the influenza virus. 14. Способ по п.13, причем условия для культивирования не являются бессывороточными.14. The method according to item 13, and the conditions for cultivation are not serum-free. 15. Способ по п.14, в условия культивирования включают среду для культивирования клеток, которая выбрана из группы, состоящей из сред MediV-105, MediV-105 с добавлением глюкозы, М-32, М-32 с добавлением глюкозы, MediV-107, MediV-107 с добавлением глюкозы.15. The method according to 14, in the cultivation conditions include a medium for cell cultivation, which is selected from the group consisting of MediV-105, MediV-105 with the addition of glucose, M-32, M-32 with the addition of glucose, MediV-107 , MediV-107 supplemented with glucose. 16. Способ по п.15, в котором среда для культивирования клеток включает MediV-105 или MediV-105 с добавлением глюкозы.16. The method of claim 15, wherein the cell culture medium comprises MediV-105 or MediV-105 supplemented with glucose. 17. Способ по любому из пп.13-16, где скорость перемешивания составляет от 80 об/мин до 120 об/мин.17. The method according to any one of claims 13-16, wherein the stirring speed is from 80 rpm to 120 rpm. 18. Способ по п.17, где скорость перемешивания составляет от 90 об/мин до 100 об/мин.18. The method according to 17, where the mixing speed is from 90 rpm to 100 rpm 19. Способ по любому из пп.13-18, в котором свежую среду или дополнительные компоненты среды вносят в культуру клеток до, в течение или после стадии (а).19. The method according to any one of paragraphs.13-18, in which fresh medium or additional components of the medium are introduced into the cell culture before, during or after stage (a). 20. Способ по п.19, в котором свежая среда или дополнительные компоненты среды включают протеазу.20. The method according to claim 19, in which the fresh medium or additional components of the medium include a protease. 21. Способ по п.20, в котором протеазой является сериновая протеаза.21. The method according to claim 20, in which the protease is a serine protease. 22. Способ по п.21, где протеазой является трипсин.22. The method according to item 21, where the protease is trypsin. 23. Способ по любому из пп.13-18, в котором некоторое количество среды для культивирования клеток удаляют или не удаляют, и замещают свежей средой перед стадией (б) или на стадии (б).23. The method according to any one of claims 13-18, wherein a certain amount of cell culture medium is removed or not removed, and replaced with fresh medium before step (b) or step (b). 24. Способ по любому из пп.13-23, в котором стадию (б) проводят при множественности заражения (МЗ) примерно от 0,00001 до примерно 0,003 FFU/клетку.24. The method according to any one of claims 13-23, wherein step (b) is carried out with a multiplicity of infection (MH) of from about 0.00001 to about 0.003 FFU / cell. 25. Способ по п.24, в котором стадию (б) проводят при множественности заражения (МЗ) примерно от 0,001 до примерно 0,003 FFU/клетку.25. The method according to paragraph 24, in which stage (b) is carried out with a multiplicity of infection (MOH) from about 0.001 to about 0.003 FFU / cell. 26. Способ по п.13, где протеазу добавляют в биореактор однократного применения до, одновременно с или после этапа (б).26. The method according to item 13, where the protease is added to a single-use bioreactor before, simultaneously with or after step (b). 27. Способ по п.26, в котором протеазой является сериновая протеаза.27. The method according to p, in which the protease is a serine protease. 28. Способ по п.27, где протеазой является трипсин. 28. The method according to item 27, where the protease is trypsin.
RU2009113671/10A 2006-09-15 2007-09-14 Cell lines of madin-derby canine kidney supporting virus growth to high tires and method to use these cells in bioreactor RU2487935C2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US84512106P 2006-09-15 2006-09-15
US60/845,121 2006-09-15
US87172106P 2006-12-22 2006-12-22
US60/871,721 2006-12-22
US91700807P 2007-05-09 2007-05-09
US60/917,008 2007-05-09
US95181307P 2007-07-25 2007-07-25
US60/951,813 2007-07-25
PCT/US2007/078527 WO2008105931A2 (en) 2006-09-15 2007-09-14 Mdck cell lines supporting viral growth to high titers and bioreactor process using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2012145173/10A Division RU2012145173A (en) 2006-09-15 2012-10-24 METHOD FOR APPLICATION OF LINE CELLS OF KIDNEY DOG MAYDIN-DERBY (MDCK) SUPPORTING THE GROWTH OF VIRUSES FOR HIGH TITLES OF THESE CELLS IN THE BIOREACTOR

Publications (2)

Publication Number Publication Date
RU2009113671A RU2009113671A (en) 2010-10-20
RU2487935C2 true RU2487935C2 (en) 2013-07-20

Family

ID=39721761

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2009113671/10A RU2487935C2 (en) 2006-09-15 2007-09-14 Cell lines of madin-derby canine kidney supporting virus growth to high tires and method to use these cells in bioreactor
RU2012145173/10A RU2012145173A (en) 2006-09-15 2012-10-24 METHOD FOR APPLICATION OF LINE CELLS OF KIDNEY DOG MAYDIN-DERBY (MDCK) SUPPORTING THE GROWTH OF VIRUSES FOR HIGH TITLES OF THESE CELLS IN THE BIOREACTOR

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2012145173/10A RU2012145173A (en) 2006-09-15 2012-10-24 METHOD FOR APPLICATION OF LINE CELLS OF KIDNEY DOG MAYDIN-DERBY (MDCK) SUPPORTING THE GROWTH OF VIRUSES FOR HIGH TITLES OF THESE CELLS IN THE BIOREACTOR

Country Status (13)

Country Link
US (3) US20080286850A1 (en)
EP (2) EP2615167A1 (en)
JP (2) JP5260525B2 (en)
KR (2) KR101464783B1 (en)
CN (2) CN101627113B (en)
AU (1) AU2007347716B2 (en)
BR (1) BRPI0716724A2 (en)
CA (1) CA2663522C (en)
ES (1) ES2473275T3 (en)
MX (1) MX2009002741A (en)
RU (2) RU2487935C2 (en)
SG (2) SG174813A1 (en)
WO (1) WO2008105931A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2573940C1 (en) * 2014-12-11 2016-01-27 Федеральное государственное бюджетное учреждение науки Институт биологии гена Российской академии наук Cell line of human kidney cancer ibgvat r 6
RU2573938C1 (en) * 2014-12-11 2016-01-27 Федеральное государственное бюджетное учреждение науки Институт биологии гена Российской академии наук Cell line of human kidney cancer ibgvat r 27

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101260084B1 (en) 2004-12-23 2013-05-03 메디뮨 엘엘씨 Non-tumorigenic mdck cell line for propagating viruses
EP2301572B1 (en) * 2005-11-01 2014-09-10 Novartis Vaccines and Diagnostics GmbH Cell-derived viral vaccines with low levels of residual cell dna
US9254318B2 (en) 2006-03-31 2016-02-09 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
RU2487935C2 (en) 2006-09-15 2013-07-20 Медиммун, Ллк. Cell lines of madin-derby canine kidney supporting virus growth to high tires and method to use these cells in bioreactor
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
CN103952376A (en) * 2008-09-24 2014-07-30 米迪缪尼有限公司 Methods for cultivating cells, propagating and purifying viruses
WO2010036774A1 (en) 2008-09-24 2010-04-01 Medimmune, Llc Methods for purification of viruses
US20110217330A1 (en) * 2008-11-05 2011-09-08 Bruno Rene Andre Novel method
JP2010143860A (en) * 2008-12-19 2010-07-01 Chisso Corp Protein stabilizer
ES2813347T3 (en) 2009-10-26 2021-03-23 Wisconsin Alumni Res Found Recombinant High Titer Influenza Viruses with Enhanced Replication in Vero Cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US20110262965A1 (en) 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
ES2568942T3 (en) * 2010-04-27 2016-05-05 Universidad Manuela Beltrán Autologous biological vaccine against cancer
TW201202425A (en) * 2010-04-28 2012-01-16 Abbott Biologicals Bv Production of viral components
RU2565546C2 (en) * 2010-08-16 2015-10-20 Севек Фармасьютикалз Гмбх Permanent human cell lines for producing influenza viruses
CN101979517B (en) * 2010-10-15 2011-12-28 普莱柯生物工程股份有限公司 Method for producing influenza viruses in large scale by using bioreactor
US9365832B2 (en) 2012-01-09 2016-06-14 Sanofi Pasteur Biologics, Llc Purification of herpes virus
CN102526720B (en) * 2012-01-11 2013-12-11 中国人民解放军军事医学科学院微生物流行病研究所 Preparation method of influenza virus vaccine
JP6152535B2 (en) * 2012-04-16 2017-06-28 公益財団法人ヒューマンサイエンス振興財団 Cell culture composition and method for producing influenza virus
EP2852662B1 (en) 2012-05-21 2020-09-16 Sanofi Pasteur Limited Herpesvirus compositions and related methods
RU2507255C1 (en) * 2012-07-23 2014-02-20 Государственное научное учреждение Всероссийский научно-исследовательский институт ветеринарной вирусологии и микробиологии Россельхозакадемии STRAIN OF DIPLOID CELLS OF LAMB SYNOVIAL MEMBRANE Ovis aries USED FOR VIROLOGICAL INVESTIGATIONS
RU2506310C1 (en) * 2012-07-23 2014-02-10 Государственное научное учреждение Всероссийский научно-исследовательский институт ветеринарной вирусологии и микробиологии Россельхозакадемии STRAIN OF DIPLOID CELLS OF SYNOVIAL MEMBRANE OF YOUNG PIG Sus scrofa, USED FOR VIROLOGY RESEARCH
WO2014105671A1 (en) 2012-12-28 2014-07-03 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens
JP6122146B2 (en) 2012-12-28 2017-04-26 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ Mycoplasma vaccine production method
KR101370512B1 (en) 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 Mdck-derived cell lines suspension-cultured in a protein-free medium and method for propagating virus using the same
EP3022296B1 (en) 2013-07-15 2022-12-28 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
JP2014088409A (en) * 2013-12-20 2014-05-15 Jnc Corp Protein stabilizer
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
CN104212768A (en) * 2014-09-18 2014-12-17 中国科学院大连化学物理研究所 Protein-free culture medium for culturing microencapsulated recombinant Chinese hamster ovary (CHO) cells and preparation method thereof
EP3591070B1 (en) * 2014-11-28 2022-12-21 uniQure IP B.V. Dna impurities in a composition comprising a parvoviral virion
CN104689311A (en) * 2014-12-31 2015-06-10 瑞普（保定）生物药业有限公司 Method for producing avian encephalomyelitis virus inactivated vaccine
JP6748067B2 (en) * 2015-03-17 2020-08-26 一般財団法人阪大微生物病研究会 Influenza virus production cells
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
CN105349499B (en) * 2015-11-06 2018-12-07 张澍 A kind of preparation method of bird flu whole virus particles marker vaccine and products thereof and purposes
WO2017143236A1 (en) 2016-02-19 2017-08-24 Yoshihiro Kawaoka Improved influenza b virus replication for vaccine development
EP3438247A4 (en) * 2016-03-29 2019-12-04 The Research Foundation for Microbial Diseases of Osaka University PROCESS FOR CULTURING MDCK CELLS
CN106119186B (en) * 2016-06-24 2019-10-08 肇庆大华农生物药品有限公司 It is a kind of for the serum free medium and preparation method thereof for cultivating mdck cell that suspends entirely
EP3299454A1 (en) * 2016-09-21 2018-03-28 Deutsches Krebsforschungszentrum Optimized method for large scale production of parvovirus h-1 in an essentially serum-free medium
CN106520700B (en) * 2016-11-10 2019-12-27 中国食品药品检定研究院 MDCK cell line for stably expressing bovine trypsinogen and application thereof
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
AU2019384164A1 (en) * 2018-11-21 2021-06-03 Kalivir Immunotherapeutics, Inc. Manufacture of virus
US11241492B2 (en) 2019-01-23 2022-02-08 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to genes in influenza viruses
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
EP4090750A4 (en) * 2020-01-17 2024-03-13 Asklepios Biopharmaceutical, Inc. Recombinant aav production
WO2021221338A1 (en) 2020-04-29 2021-11-04 에스케이바이오사이언스(주) Influenza virus production method using disposable culture process system, and test for quickly checking conditions for influenza virus antigen purification
KR102444684B1 (en) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) Method for producing influenza virus using single-use cultivation process system
EP4217087A2 (en) * 2020-09-23 2023-08-02 Codiak BioSciences, Inc. Process for preparing extracellular vesicles
CN116376810A (en) * 2023-04-26 2023-07-04 上海奥浦迈生物科技股份有限公司 MDCK cell serum-free adherence culture domestication method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726907B1 (en) * 1996-11-20 2004-04-27 Introgen Therapeutics, Inc. Purified adenoviral compositions
WO2006018977A1 (en) * 2004-08-16 2006-02-23 Ntn Corporation Needle roller bearing

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO162160C (en) 1987-01-09 1989-11-15 Medi Cult As SERUM-FREE GROWTH MEDIUM AND USE THEREOF.
US5118513A (en) 1987-07-02 1992-06-02 The Procter & Gamble Company Method for enhancing bioavailability of iron-calcium mineral supplements
US6001634A (en) 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US20060019350A1 (en) 1989-08-28 2006-01-26 Peter Palese Recombinant negative strand RNA virus expression system and vacccines
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5840520A (en) 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5786199A (en) 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
SU1698288A1 (en) 1990-02-01 1991-12-15 Всесоюзный научно-исследовательский институт гриппа Strain of virus influenza a/leningrad/325/88 for preparation of influenzal diagnosticum
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
US6245549B1 (en) * 1990-06-28 2001-06-12 Connaught Laboratories Limited Production of virus and purification of viral envelope proteins for vaccine use
GB9215834D0 (en) 1992-07-24 1992-09-09 Celltech Ltd Cell culture
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US5690937A (en) 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene
DE19612967A1 (en) 1996-04-01 1997-10-02 Behringwerke Ag Process for the propagation of influenza viruses in cell culture, and the influenza viruses obtainable by the process
DE19612966B4 (en) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK cells and methods of propagating influenza viruses
WO1998008934A1 (en) 1996-08-30 1998-03-05 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
US20040171152A1 (en) 1996-10-10 2004-09-02 Invitrogen Corporation Animal cell culture media comprising non-animal or plant-derived nutrients
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6884414B1 (en) 1997-04-30 2005-04-26 Mount Sinai School Of Medicine Of New York University Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
AU7081500A (en) 1999-08-27 2001-03-26 Invitrogen Corporation Metal binding compounds and their use in cell culture medium compositions
JP4698112B2 (en) * 2000-03-03 2011-06-08 一般財団法人化学及血清療法研究所 Cells capable of serum-free culture and suspension culture, and method for producing virus for vaccine using the cells
EP1317559B1 (en) 2000-04-28 2009-01-07 St. Jude Children's Research Hospital Dna transfection system for the generation of infectious negative strand rna virus
CN1194005C (en) * 2000-06-01 2005-03-23 长春长生生物科技股份有限公司 Producing influenza killed vaccine by Sepharose 4FF column chromatography technology
ES2330411T3 (en) * 2000-06-23 2009-12-10 Intervet International Bv SYNTHETIC VIRUS RESPIRATORY BOVINE DENIED.
US20040241139A1 (en) 2000-07-20 2004-12-02 Gerd Hobom Recombinant influenza viruses with bicistronic vRNAs coding for two genes in tandem arrangement
US6593123B1 (en) * 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
DE10144903A1 (en) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Replication of virus in cell cultures, useful for preparing vaccines and diagnostic reagents, where replication of cells and virus is simultaneous
DE10144906B4 (en) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Process for the large-scale production of vaccines
ATE384785T1 (en) 2001-12-07 2008-02-15 Crucell Holland Bv PRODUCTION OF VIRUSES, VIRUS ISOLATES, AND VACCINES
US6951752B2 (en) 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
CA2477037C (en) 2002-02-21 2014-12-09 Mount Sinai School Of Medicine Recombinant negative strand virus rna expression systems and vaccines
AU2003230908A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
CN103540568A (en) 2002-04-26 2014-01-29 米迪缪尼有限公司 Multi plasmid system for the production of influenza virus
EP2287288B1 (en) * 2002-07-09 2012-11-07 Baxter International Inc. Animal protein free media for cultivation of cells
WO2004020971A2 (en) 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US20060002862A1 (en) * 2002-12-17 2006-01-05 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
JP4617300B2 (en) 2003-02-25 2011-01-19 メディミューン，エルエルシー Methods for producing influenza vaccine compositions
WO2004083397A2 (en) * 2003-03-18 2004-09-30 Wyeth Holdings Corporation Process for increasing rsv surface glycoprotein yields using a mutant strain of rsv
US7405068B2 (en) * 2003-05-02 2008-07-29 Tate & Lyle Ingredients Americas, Inc. Pyruvate producing yeast strain
EP1631673A2 (en) 2003-05-28 2006-03-08 Wisconsin Alumni Research Foundation Recombinant influenza vectors with a polii promoter and ribozymes
WO2004110484A1 (en) 2003-06-18 2004-12-23 Gosudarstvenny Nauchny Tsentr Virusologii I Biotekhnologii 'vektor' Method for producing a live tissue-cultural vaccine against influenza virus
WO2005010849A1 (en) 2003-07-31 2005-02-03 Louis Auer Cardiovascular disorder simulation device
WO2005026333A1 (en) 2003-09-09 2005-03-24 Japan Science And Technology Agency Technique for suspension culture of adhesive cells using protease and method of producing virus with the use of the cells as host
ATE469972T1 (en) 2003-12-23 2010-06-15 Medimmune Llc MULTIPLASMID SYSTEM FOR GENERATING THE FLU VIRUS
RS50531B (en) * 2004-03-01 2010-05-07 Ares Trading S.A. Use of a serum-free cell culture medium for the production of il-18bp in mammalian cells
JP4650798B2 (en) 2004-04-19 2011-03-16 デンカ生研株式会社 Virus production method
CA2559496A1 (en) 2004-04-27 2005-11-17 Baxter International Inc. Stirred-tank reactor system
AU2005245943A1 (en) 2004-05-20 2005-12-01 Id Biomedical Corporation Process for the production of an influenza vaccine
ES2633471T3 (en) 2004-10-06 2017-09-21 Medimmune, Llc Cold-stable flu vaccine compositions
EP1824990B1 (en) 2004-12-08 2015-02-18 MedImmune, LLC Methods of producing influenza vaccine compositions
KR101260084B1 (en) 2004-12-23 2013-05-03 메디뮨 엘엘씨 Non-tumorigenic mdck cell line for propagating viruses
JP4693839B2 (en) 2005-03-10 2011-06-01 共立製薬株式会社 Cell line that can be cultured without animal-derived components, method for producing the same, virus production method using the same, and vaccine production method
US7534596B2 (en) * 2006-02-10 2009-05-19 Solohill Engineering, Inc. Method and device for producing vaccine
PL2007883T3 (en) 2006-04-20 2012-07-31 Wyeth Llc Purification processes for isolating purified vesicular stomatitis virus from cell culture
US8778353B2 (en) 2006-05-01 2014-07-15 Technovax, Inc. Influenza virus-like particle (VLP) compositions
RU2487935C2 (en) 2006-09-15 2013-07-20 Медиммун, Ллк. Cell lines of madin-derby canine kidney supporting virus growth to high tires and method to use these cells in bioreactor
EP1982727A1 (en) 2007-04-17 2008-10-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for purification of viral proteins
WO2010036774A1 (en) 2008-09-24 2010-04-01 Medimmune, Llc Methods for purification of viruses
CN103952376A (en) * 2008-09-24 2014-07-30 米迪缪尼有限公司 Methods for cultivating cells, propagating and purifying viruses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726907B1 (en) * 1996-11-20 2004-04-27 Introgen Therapeutics, Inc. Purified adenoviral compositions
WO2006018977A1 (en) * 2004-08-16 2006-02-23 Ntn Corporation Needle roller bearing

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2573940C1 (en) * 2014-12-11 2016-01-27 Федеральное государственное бюджетное учреждение науки Институт биологии гена Российской академии наук Cell line of human kidney cancer ibgvat r 6
RU2573938C1 (en) * 2014-12-11 2016-01-27 Федеральное государственное бюджетное учреждение науки Институт биологии гена Российской академии наук Cell line of human kidney cancer ibgvat r 27

Also Published As

Publication number Publication date
KR20140075022A (en) 2014-06-18
CA2663522C (en) 2015-06-02
EP2069480B1 (en) 2014-03-19
US20130052717A1 (en) 2013-02-28
BRPI0716724A2 (en) 2013-10-01
MX2009002741A (en) 2009-05-11
CN101627113A (en) 2010-01-13
WO2008105931A2 (en) 2008-09-04
KR101464783B1 (en) 2014-11-26
JP5260525B2 (en) 2013-08-14
US8357376B2 (en) 2013-01-22
CA2663522A1 (en) 2008-09-04
JP2010503412A (en) 2010-02-04
US20080286850A1 (en) 2008-11-20
SG10201501780QA (en) 2015-04-29
AU2007347716B2 (en) 2013-06-20
US20100112669A1 (en) 2010-05-06
AU2007347716A1 (en) 2008-09-04
ES2473275T3 (en) 2014-07-04
WO2008105931A3 (en) 2009-02-19
CN101627113B (en) 2013-04-24
RU2012145173A (en) 2014-04-27
RU2009113671A (en) 2010-10-20
CN103361319A (en) 2013-10-23
US8846032B2 (en) 2014-09-30
EP2069480A2 (en) 2009-06-17
JP2013153762A (en) 2013-08-15
EP2069480A4 (en) 2011-03-30
SG174813A1 (en) 2011-10-28
KR20090057444A (en) 2009-06-05
EP2615167A1 (en) 2013-07-17

Similar Documents

Publication Publication Date Title
RU2487935C2 (en) Cell lines of madin-derby canine kidney supporting virus growth to high tires and method to use these cells in bioreactor
Shen et al. Development of suspension adapted Vero cell culture process technology for production of viral vaccines
Gallo–Ramírez et al. Bioreactor concepts for cell culture-based viral vaccine production
CN100335619C (en) Method for large scale production of virus antigen
CN110272864B (en) Vero33 cell strain adapting to serum-free suspension culture and domestication method and application thereof
Hanson et al. A broadly applicable method to characterize large DNA viruses and adenoviruses based on the DNA polymerase gene
CN107312746B (en) Large-scale full-suspension culture method for porcine circovirus type 2
DE60017234D1 (en) vaccine production
CN107460156B (en) Serum-free full-suspension MDCK cell strain and application thereof in production of influenza virus
Wu et al. High cell density perfusion process for high yield of influenza A virus production using MDCK suspension cells
CN110237246B (en) Method for culturing inactivated vaccine for avian influenza (H9) by using full-suspension cells
CN104726392B (en) A kind of method of the suspension mammalian cell system preparing free serum culture and its cell line prepared and application
Fuenmayor et al. Extended gene expression for Gag VLP production achieved at bioreactor scale
JP2013515473A5 (en)
CN103394081B (en) WAVE wave bioreactor is utilized to produce the method for avian influenza vaccine
CN101831412A (en) Method for producing porcine reproductive and respiratory syndrome viruses (PRRSV) in large scale
Arifin et al. Production of Newcastle disease virus by Vero cells grown on cytodex 1 microcarriers in a 2‐litre stirred tank bioreactor
CN108611351B (en) ID1 gene sgRNA, ID1 gene knockout method, BHK-21 cell line and use thereof
CN102861329A (en) Production method of canine parvovirus inactivated vaccine by utilizing bioreactor
US9932562B2 (en) Drain down and re-feed of microcarrier bioreactor
JP6851827B2 (en) Large-scale production of virus in cell culture
CN1617923A (en) Method of large scale production of hepatitis a virus
Wang et al. Suspension culture process for H9N2 avian influenza virus (strain Re-2)
Afzal et al. Assessment of mumps virus growth on various continuous cell lines by virological, immunological, molecular and morphological investigations
Madeline et al. Culturing a Duck ES-derived cell line in single-use bioreactors

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160915